Education
About Us
Working with TipRanks
Follow Us
Schrodinger, Inc. (SDGR)
:SDGR
SDGR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.60 - $28.47
Previous CloseN/A
Volume166.74K
Average Volume (3M)981.82K
Market Cap
$1.44B
Enterprise Value$1.13B
Total Cash (Recent Filing)$500.30M
Total Debt (Recent Filing)$116.16M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Nov 12, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding64,212,690
10 Day Avg. Volume968,556
30 Day Avg. Volume981,821
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue4.90
Enterprise Value/Gross Profit7.83
Enterprise Value/Ebitda-6.01
Forecast
1Y Price Target
$30.86Price Target Upside54.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
EfficacyThe initial clinical data for Schrodinger's MAL T1 inhibitor, SGR-1505, shows activity across multiple malignancies, particularly in CLL/SLL and WM, with no dose-limiting toxicities observed.
Industry ImpactSchrödinger's computational drug discovery platform will disrupt the biopharma industry, leading the transition to in silico drug discovery.
Safety ProfileThe safety profile of SGR-1505 remained largely consistent and favorable compared to competing treatments, with some adverse events but no severe bilirubin increases.
Bears Say
Adverse Events25% of patients experienced Grade 3 or higher treatment-related adverse events, including decreases in neutrophil count and increases in blood bilirubin.
Market SkepticismThere is skepticism about how SGR-1505 differentiates itself from competing assets, creating pressure on management to execute business development strategies.
Stock PerformanceShares are down over 10% as concerns arise about bilirubin levels potentially indicating a liver toxicity signal for the MALT1 class.
Schrodinger News
SDGR FAQ
What was Schrodinger, Inc.’s price range in the past 12 months?
Schrodinger, Inc. lowest stock price was $16.60 and its highest was $28.47 in the past 12 months.
What is Schrodinger, Inc.’s market cap?
Schrodinger, Inc.’s market cap is $1.44B.
When is Schrodinger, Inc.’s upcoming earnings report date?
Schrodinger, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.
How were Schrodinger, Inc.’s earnings last quarter?
Schrodinger, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.768 by $0.178.
Is Schrodinger, Inc. overvalued?
According to Wall Street analysts Schrodinger, Inc.’s price is currently Undervalued.
Does Schrodinger, Inc. pay dividends?
Schrodinger, Inc. does not currently pay dividends.
What is Schrodinger, Inc.’s EPS estimate?
Schrodinger, Inc.’s EPS estimate is -0.77.
How many shares outstanding does Schrodinger, Inc. have?
Schrodinger, Inc. has 64,212,690 shares outstanding.
What happened to Schrodinger, Inc.’s price movement after its last earnings report?
Schrodinger, Inc. reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.768. Following the earnings report the stock price went up 0.675%.
Which hedge fund is a major shareholder of Schrodinger, Inc.?
Currently, no hedge funds are holding shares in SDGR
Schrodinger Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.86 (54.38% Upside)
$30.86 (54.38% Upside)
Blogger Sentiment
Bullish
SDGR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 91.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.25%
12-Months-Change
Fundamentals
Return on Equity
-44.40%
Trailing 12-Months
Asset Growth
-0.02%
Trailing 12-Months
Company Description
Schrodinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Company Deck
SDGR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong revenue growth and strategic progress in partnerships and R&D, particularly in software and drug discovery. However, there were challenges, including a decline in professional services revenue, lower software gross margins, and increased net loss. Despite these issues, the company's overall outlook for 2025 remains positive.View all SDGR earnings summariesSDGR Stock 12 Month Forecast
Average Price Target
$30.86
▲(54.38% Upside)
Technical Analysis
Simulations Plus
―
Veeva Systems
―
Certara
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.41% Insiders
21.14% Mutual Funds
0.08% Other Institutional Investors
51.13% Public Companies and
Individual Investors